13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q1 2023. See the latest, Q2 2026 →
Reported value
$14.55B
+26% on the quarter before
Positions
221
6 new · 17 sold out
Top 10
51.5%
of the value
Est. gain
+$2.69B
on stocks held all quarter
Est. return
+24.7%
on those stocks since Q4 2022
Positions as of Mar 31, 2023, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q4 2022. Striped tiles are options.
Largest buys
Since Q4 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Coinbase~$174.8MAdded · 2.8% → 5.5%+2,586,742 shares
- Tesla~$168.9MAdded · 4.9% → 7.8%+814,163 shares
- Block~$100.8MAdded · 4.9% → 4.9%+1,467,630 shares
- Unity Software Inc~$43.3MAdded · 2.7% → 2.7%+1,335,347 shares
- Teladoc Health Inc~$42.9MAdded · 3.9% → 3.7%+1,655,740 shares
- Shopify Inc~$33.9MAdded · 4.0% → 4.6%+706,688 shares
- Ginkgo Bioworks Holdings Inc~$27.1MAdded · 2.1% → 1.5%+20,372,918 shares
- Roblox~$25.3MAdded · 2.1% → 2.8%+561,670 shares
- Roku Inc~$24.3MAdded · 4.3% → 5.6%+368,450 shares
- Robinhood~$24.2MAdded · 2.1% → 2.1%+2,488,889 shares
Largest sells
Since Q4 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Exact Sciences Corp~$316.1MCut · 6.9% → 5.3%−4,661,303 shares
- Twilio~$77.3MCut · 3.1% → 2.9%−1,159,944 shares
- Fate Therapeutics Inc~$42.5MSold out · 0.4% → 0.0%−4,214,863 shares
- Monday.Com Ltd~$32.8MCut · 0.3% → 0.0%−230,056 shares
- Nvidia~$30.2MCut · 0.7% → 0.8%−108,862 shares
- MercadoLibre~$21.8MCut · 0.6% → 0.5%−16,531 shares
- Draftkings Inc~$21.3MCut · 2.5% → 3.2%−1,100,829 shares
- Materialise Nv~$17.2MCut · 0.3% → 0.1%−2,071,260 shares
- Incyte Corp~$16.1MCut · 0.7% → 0.4%−222,408 shares
- Adobe~$14.7MSold out · 0.1% → 0.0%−43,701 shares
Holdings
As of Mar 31, 2023. Changes are in shares against Dec 31, 2022, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TeslaCommon Stock · shares +18% · price +68.4% | 7.8% | $1.13B | +$389.8M | ||||||||
| Roku IncCommon Stock · shares +3.0% · price +61.7% | 5.6% | $821.7M | +$304.3M | ||||||||
| ZoomCommon Stock · shares +2.4% · price +9.0% | 5.5% | $802.4M | +$64.8M | ||||||||
| CoinbaseCommon Stock · shares +28% · price +90.9% | 5.5% | $795.7M | +$295.7M | ||||||||
| UiPathCommon Stock · shares +1.9% · price +38.2% | 5.4% | $788.3M | +$213.7M | ||||||||
| Exact Sciences CorpCommon Stock · shares −29% · price +37.0% | 5.3% | $771.6M | +$208.2M | ||||||||
| BlockCommon Stock · shares +16% · price +9.2% | 4.9% | $718.8M | +$52.3M | ||||||||
| Shopify IncCommon Stock · shares +5.3% · price +38.1% | 4.6% | $670.5M | +$175.7M | ||||||||
| Teladoc Health IncCommon Stock · shares +8.7% · price +9.5% | 3.7% | $533.1M | +$42.6M | ||||||||
| Draftkings IncCommon Stock · shares −4.4% · price +70.0% | 3.2% | $463.3M | +$190.7M | ||||||||
| TwilioCommon Stock · shares −16% · price +36.1% | 2.9% | $416.4M | +$110.4M | ||||||||
| RobloxCommon Stock · shares +6.6% · price +58.0% | 2.8% | $406.0M | +$139.8M | ||||||||
| Unity Software IncCommon Stock · shares +12% · price +13.5% | 2.7% | $399.3M | +$42.2M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +4.4% · price +6.8% | 2.5% | $366.6M | +$22.4M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares +2.0% · price +11.3% | 2.5% | $361.4M | +$35.9M | ||||||||
| Pagerduty IncCommon Stock · shares −2.6% · price +31.7% | 2.4% | $343.9M | +$82.8M | ||||||||
| Pacific Biosciences Of CaliforCommon Stock · shares +8.0% · price +41.6% | 2.2% | $321.4M | +$87.4M | ||||||||
| RobinhoodCommon Stock · shares +8.5% · price +19.3% | 2.1% | $308.1M | +$45.9M | ||||||||
| Beam Therapeutics IncCommon Stock · shares +4.4% · price −21.7% | 1.8% | $262.5M | −$69.7M | ||||||||
| 10x Genomics IncCommon Stock · shares −3.7% · price +53.1% | 1.6% | $231.8M | +$80.4M | ||||||||
| Ginkgo Bioworks Holdings IncCommon Stock · shares +14% · price −21.3% | 1.5% | $219.1M | −$52.0M | ||||||||
| Veracyte IncCommon Stock · shares +1.3% · price −6.0% | 1.3% | $187.5M | −$11.9M | ||||||||
| NvidiaCommon Stock · shares −21% · price +90.1% | 0.79% | $115.1M | +$54.5M | ||||||||
| Twist Bioscience CorpCommon Stock · shares +7.1% · price −36.7% | 0.74% | $108.3M | −$58.5M | ||||||||
| SchrödingerCommon Stock · shares +1.4% · price +40.9% | 0.71% | $102.9M | +$29.4M | ||||||||
| Total · 221 positions | 100% | $14.55B | +$2.69B |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q4 2022 to Q1 2023: 214 stocks held throughout, up $2.69B (+24.7%).
- Tesla+$389.8M+68%
- Roku Inc+$304.3M+62%
- Coinbase+$295.7M+91%
- UiPath+$213.7M+38%
- Exact Sciences Corp+$208.2M+37%
- Caredx Inc−$14.0M−20%
- Verve Therapeutics Inc−$21.5M−25%
- Ginkgo Bioworks Holdings Inc−$52.0M−21%
- Twist Bioscience Corp−$58.5M−37%
- Beam Therapeutics Inc−$69.7M−22%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |